Rare blood cancer and bone marrow failure diseases are often difficult to diagnose and even harder to explain. AAMDSIF brings international experts to your computer, tablet or smartphone using language that is easy to understand in a convenient one hour format. We have hundreds of webinars available for you to watch at any time you want!
|Wednesday, March 3, 2021 - 2:00pm||Understanding Bone Marrow Failure Syndromes|
|Monday, March 8, 2021 - 3:00pm||ASH 2020: MDS and AML Updates for Patients|
|Thursday, March 18, 2021 - 2:00pm||COVID-19 Update: Vaccinations for Bone Marrow Failure Patients|
|Monday, March 22, 2021 - 12:00pm||New Transplant Advances for Patients|
|Friday, April 23, 2021 - 2:00pm||Intimacy and Bone Marrow Failure|
|Tuesday, April 27, 2021 - 2:00pm||Haploidentical Transplant for MDS|
Seth Corey, MD, MPH (Cleveland Clinic), led an informative session for patients of all ages about the causes of bone marrow failure diseases like aplastic anemia, PNH, MDS and AML. Dr. Corey explains the difference between acquired and genetic disease, how that difference can affect treatment options and prognosis.
Rabi Hanna, MD (Cleveland Clinic) helps aplastic anemia patients and families understand the treatment options including new thinking on transplants from alternative donors for patients with acquired aplastic anemia. Dr. Hanna will also gives an update on the most promising developments currently in clinical trial.
Dr. Seth Rotz and Taylor Buss (Cleveland Clinic) lead a panel discussion with two patients, Paige and Justin who were diagnosed with bone marrow failure disease while they were teenagers or young adults, underwent treatment and are now survivors. Dr. Rotz gives an overview of what characteristics he sees in his most successful patients and then Taylor Buss asks questions of our survivors - from dating to life as a young professional.
Hetty Carraway, MD (Cleveland Clinic) leads an informative session for MDS patients who want to know more about how genetic mutations can affect treatment options and how doctors evaluate the risk of MDS progression based on international criteria.
Staci Arnold, MD, MBA, MPH (Emory University) shares her extensive research on what quality of life outcomes are most important to bone marrow failure disease patients and families and how to make your life better during diagnosis, treatment and survivorship.
Jaroslaw Maciejewski, MD, PhD and Bumikha Patel, MD (Cleveland Clinic), give an important update for PNH patients and families on new treatment options as well as promising drugs currently in clinical trial.
Amit K. Verma, MBBS, is a Professor in the Departments of Medicine (Oncology) and Development & Molecular Biology at Albert Einstein School of Medicine. Dr. Verma is the Director of the Division of Hemato-Oncology, Montefiore Department of Oncology. His primary area of research is in MDS.
Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at the Yale School of Medicine. Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML) and is an international expert in the clinical management and research of myeloid malignancies.
Dr. Verma and Dr. Zeidan give an update on the two newest treatments for MDS patients, INQOVI and REBLOYZL. They also give a brief update on what is in the immediate pipeline for MDS patients and what can be expected into 2021.
Elizabeth Griffiths, MD is an Associate Professor at the State University of New York (SUNY) at Buffalo and a faculty member of the Roswell Park Comprehensive Cancer Center-SUNY Buffalo graduate training programs in the departments of Pharmacology and Therapeutics, Translational Medicine and Immunology. Prior to joining Roswell Park in 2010, Dr. Griffiths completed a five year medical oncology and hematology fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, MD. Dr. Griffiths is board certified in hematology, oncology and internal medicine.
In this webinar, Dr. Griffiths gives a brief overview of what PNH is and how it affects patients, an update on the current treatment options for PNH patients and then answers more than a dozen questions from patients and family members.
Eytan M. Stein, MD is a Oncologic Hematologist at Sloan Kettering emorial Cancer Center who specializes in caring for people with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. He earned his medical degree from Northwestern University and is board certified in Internal Medicine, Medical Oncology, and Hematology. Dr. Stein is an active clinical researcher developing new and innovative approaches to treating acute myeloid leukemia (AML) and serves as the principal investigator on a wide variety of clinical trials.In this webinar, Dr. Eytan M. Stein discusses the important issues specific to young adults with MDS, from long-term prognosis and fertility concerns to next generation sequencing and clinical trial opportunities.
Ryotaro Nakamura, MD is Professor, Department of Hematology & Hematopoietic Cell Transplantation; Director, Center for Stem Cell Transplantation at City of Hope.
Dr. Nakamura discusses the how the best practices for treating aplastic anemia and MDS have changed to include transplant as a realistic option for many patients over 40. With new conditioning regimes and improved matching, many patients can have a successful transplant well into their 70s. Dr. Nakamura also gives an overview of how aplastic anemia and MDS affect the bone marrow, a critical part of the decisionmaking process for determining if a transplant is an option.
Bhumika Patel, MD, is a board certified hematologist/oncologist who was appointed to the Cleveland Clinic Taussig Cancer Center in 2019, following two successful fellowships. Dr. Patel is an active researcher, contributing to more than 40 studies over the last three years with a focus on bone marrow failure diseases.
In this webinar, Dr. Patel discusses the specific concerns of women living with aplastic anemia, from the newly diagnosed to longer-term survivors and includes a robust Q & A sessions with input from women living with aplastic anemia.
Dr. Bhatt and Dr. Zimmer discuss important information about how and when to treat infectious disease in patients who have had a transplant. This webinar is appropriate for patients who are contemplating a transplant and those who have already had one.
Vijaya R. Bhatt, MD, MBBS, is Assistant Professor, Internal Medicine in the Division of Oncology & Hematology and the University of Nebraska Medical Center. Dr. Bhatt sees patients at the Fred & Pamela Buffett Cancer Center where he specializes in hematopoietic stem cell transplant, post-transplant complications, graft-versus-host disease, leukemias, myeloid disorders and benign hematologic disorders.
Dr. Bhatt is board certified in Hematology and Medical Oncology as well as being a well-regarded researcher. He has published numerous journal articles, papers and analyses on topics including the treatment of infectious disease in transplant patients.
Andrea Zimmer, MD, joins the webinar to provide her perspective in infection diseases. Dr. Zimmer is Assistant Professor, Department of Internal Medicine, Co-Director, Graduate Medical Education Curriculum, Microbiology & Infectious Diseases Block at the University of Nebraska School of Medicine. Dr. Zimmer treats patients at the Fred & Pamela Buffett Cancer Center, providing guidance and support to patients and health care professionals in managing the risks of infectious disease.
Tiffany N. Tanaka, MD, is a board-certified hematologist specializing in the diagnosis and treatment of blood cancers and blood disorders, with an emphasis on myeloid malignancies. Dr. Tanaka provides an overview of the diagnostic and treatment considerations for patients who have aplastic anemia and hypoplastic MDS. This overlapping set of bone marrow failure diseases raises critical questions for patients and health care professionals.
Holly Comer, BSN, ANP-BC, has been an oncology nurse for 30 years and has been a nurse practitioner for the last 14 years. Ms. Comer is with Siteman Cancer Center at Barnes-Jewish Hospital & Washington University School of Medicine where she has been part of the Bone Marrow Transplant team for the last 26 years. She also served as a nurse during the Gulf War. Ms. Comer is actively involved in clinical research, most recently serving as the principal investigator for "Bone Loss in Allogeneic Transplant Patients", the results of which will be covered during her webinar.
Holly Comer, MSN, ANP-BC provides a thorough overview of the concerns of long term transplant survivors related to bone health and disease. Ms. Comer also provides an update on a recent study she led entitled "Bone Loss in Allogenic Transplant Patients".
Kathleen Moore, MD is Director, Oklahoma TSET Phase I Program; Associate Professor, Section of Gynecologic Oncology and is an associate professor in the section of gynecologic oncology and serves as the director of the Oklahoma TSET Phase I Clinical Trials Program, the state’s only phase I clinical trials program. She is the Jim and Christy Everest Endowed Chair in Cancer Research as well as the director of the gynecologic oncology fellowship program. She also serves as the Associate Director of Clinical Research and Medical Director of the Clinical Trials Office for the Stephenson Cancer Center.
Dr. Moore discusses the unique concerns of female patients who develop Secondary MDS/AML after chemotherapy treatment. This session includes current treatment options as well as a review of what is currently in clinical trial, including Dr. Moore's own work in drug development.
Carlos E. Vigil, MD is a Hematologist at the University of Iowa Hospitals and Clinics and Clinical Assistant Professor of Internal Medicine - Hematology, Oncology and Blood and Marrow Transplantation at the University of Iowa Carver College of Medicine. Dr. Vigil received his MD from the Universidad Peruana Cayetano Heredia and is engaged in academic research as well as working directly with patients in clinic.
Dr. Vigil discusses autoimmune disorders and MDS (myelodysplastic syndromes) including an assessment of the overlap between autoimmune disorders and bone marrow failure disease, the impact this can have on treatment options and on patient prognosis.
Swapna Thota, MD joined Roswell Park in 2017 where she specializes in caring for patients with acute leukemias, MDS and other blood cancers. She holds a dual appointment as Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo. Dr. Thota's research focuses on hematologic malignancies, especially on novel drug development to improve outcomes in patients with blood cancers.
Dr. Thota discusses the complexities of determining the best course of treatment for patients with moderate aplastic anemia.